.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech expect to specify on the Nasdaq under the symbol “BIOA,” according to files filed with the Securities as well as Exchange Payment. The business has actually not publicly shared an assumed financial quantity for the offering.The clinical-stage firm boasts lead applicant azelaprag, an orally supplied little particle slated to get in period 2 testing in combination with semaglutide– marketed by Novo Nordisk under brand Wegovy for fat loss– in the initial one-half of upcoming year. Semaglutide is likewise sold as Ozempic as well as Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually designed to integrate effectively with GLP-1 medicines, increasing fat burning while preserving muscular tissue mass. The investigational drug was actually discovered to become well-tolerated among 265 individuals across 8 period 1 tests, depending on to BioAge.Recently, BioAge achieved the support of Lilly to run a trial integrating azelaprag along with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes as Mounjaro and Zepbound for weight management. The companions are currently administering a phase 2 trial of azelaprag and also tirzepatide, with topline outcomes expected in the third one-fourth of 2025.The biotech is likewise preparing a the hormone insulin sensitiveness proof-of-concept trial evaluating azelaprag as a monotherapy in the very first fifty percent of upcoming year to support possible evidence growth.
On top of that, the company prepares to talk to the FDA for consent in the 2nd fifty percent of 2025 to release individual screening for an NLRP3 prevention targeting metabolic diseases and neuroinflammation.BioAge’s anticipated transfer to the general public market observes a slight uptick in organized biotech IPOs from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the recent IPO landscape is actually a “blended photo,” with high-grade business still debuting on the general public markets, only in minimized varieties, depending on to PitchBook.